Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
13.27
+0.95 (7.71%)
At close: Jan 6, 2026, 4:00 PM EST
13.21
-0.06 (-0.45%)
After-hours: Jan 6, 2026, 4:17 PM EST
Tenax Therapeutics Employees
As of December 31, 2024, Tenax Therapeutics had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$7,221,000
Market Cap
538.37M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | 0 | - |
| Dec 31, 2023 | 6 | -2 | -25.00% |
| Dec 31, 2022 | 8 | -1 | -11.11% |
| Dec 31, 2021 | 9 | -1 | -10.00% |
| Dec 31, 2020 | 10 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TENX News
- 1 day ago - Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing - Seeking Alpha
- 20 days ago - Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment - GlobeNewsWire
- 6 weeks ago - Tenax Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Tenax Therapeutics, Inc. (TENX) Discusses Scientific Rationale and Development Strategy for TNX-103 in PH-HFpEF Transcript - Seeking Alpha
- 7 weeks ago - Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF - GlobeNewsWire
- 2 months ago - Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 4 months ago - Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF - GlobeNewsWire